Yahoo Search Búsqueda en la Web

Entrar

Resultado de búsqueda

  1. pubmed.ncbi.nlm.nih.gov › 31590988Durvalumab plus platinum-etoposide versus platinum-etoposide ......

    23 de nov. de 2019 · The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum-etoposide) in treatment-naive patients with ES-SCLC. Methods: This randomised, open-label, phase 3 trial was done at 209 sites across 23 countries.

  2. www.thelancet.com › journals › lancetLogin to your account - The Lancet

    4 de oct. de 2019 · The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum–etoposide) in treatment-naive patients with ES-SCLC.

  3. Videos

    Ver todo

  4. www.esmoopen.com › article › S2059-7029(22)00029-1Durvalumab, with or without tremelimumab, plus platinum-etoposide...

    11 de mar. de 2022 · In the phase III CASPIAN study, first-line durvalumab in combination with etoposide plus either cisplatin or carboplatin (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small-cell lung cancer (ES-SCLC).

  5. pubmed.ncbi.nlm.nih.gov › 33285097Durvalumab, with or without tremelimumab, plus platinum ... -...

    Background: First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum-etoposide) showed a significant improvement in overall survival versus platinum-etoposide alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) in the CASPIAN study.

  6. www.thelancet.com › pdfs › journalsDurvalumab plus platinum–etoposide versus platinumâ ...

    The CASPIAN trial assessed durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum–etoposide) in treatment-naive patients with ES-SCLC.

  7. ascopubs.org › doi › 10Durvalumab ± tremelimumab + platinum-etoposide in first-line...

    25 de may. de 2020 · Background: CASPIAN is an open-label, Phase 3 study of durvalumab (D) ± tremelimumab (T) + etoposide and either cisplatin or carboplatin (EP) for pts with 1L ES-SCLC.

  8. aacrjournals.org › clincancerres › articleDurvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage...

    16 de feb. de 2024 · In the CASPIAN trial, first-line durvalumab plus platinum-etoposide (EP) significantly improved overall survival (OS) versus EP alone in extensive-stage small cell lung cancer (ES-SCLC). We report exploratory analyses of CASPIAN outcomes by programmed cell death ligand-1 (PD-L1) expression and tissue tumor mutational burden (tTMB).